A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 50 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- Blood Cancer United
- Tags
- Natural Killer (NK) Cells, Chemotherapy
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1589
- NCT Identifier
- NCT04024761
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.